STAT3/mitophagy axis coordinates macrophage NLRP3 inflammasome activation and inflammatory bone loss

Lingxin Zhu,Zijun Wang,Xiaoyue Sun,Jingjing Yu,Ting Li,Huan Zhao,Yaoting Ji,Bin Peng,Minquan Du
DOI: https://doi.org/10.1002/jbmr.4756
IF: 6.39
2022-12-13
Journal of Bone and Mineral Research
Abstract:Signal transducer and activator of transcription 3 (STAT3), a cytokine‐responsive transcription factor, is known to play a role in immunity and bone remodeling. However, whether and how STAT3 impacts macrophage NLR family pyrin domain containing 3 (NLRP3) inflammasome activation associated with inflammatory bone loss remains unknown. Here, STAT3 signaling is hyperactivated in macrophages in the context of both non‐sterile and sterile inflammatory osteolysis, and this was highly correlated with the cleaved interleukin‐1β (IL‐1β) expression pattern. Strikingly, pharmacological inhibition of STAT3 markedly blocks macrophage NLRP3 inflammasome activation in vitro, thereby relieving inflammatory macrophage‐amplified osteoclast formation and bone resorptive activity. Mechanistically, STAT3 inhibition in macrophages triggers PTEN‐induced kinase 1 (PINK1)‐dependent mitophagy that eliminates dysfunctional mitochondria, reverses mitochondrial membrane potential collapse, and inhibits mitochondrial reactive oxygen species release, thus inactivating the NLRP3 inflammasome. In vivo, STAT3 inhibition effectively protects mice from both infection‐induced periapical lesions and aseptic titanium particle‐mediated calvarial bone erosion with potent induction of PINK1 and downregulation of inflammasome activation, macrophage infiltration, and osteoclast formation. This study reveals the regulatory role of the STAT3/mitophagy axis at the osteo‐immune interface and highlights a potential therapeutic intervention to prevent inflammatory bone loss. This article is protected by copyright. All rights reserved.
endocrinology & metabolism
What problem does this paper attempt to address?